Axsome Therapeutics (AXSM) vs BioMarin Pharmaceutical (BMRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Axsome Therapeutics (AXSM) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 37.4% versus a gain of 0.4%. Over five years, AXSM leads with a +319.8% price change compared with -27.7% for BMRN. BioMarin Pharmaceutical is the larger company by market cap ($10.61 billion vs $8.82 billion), about 1.2 times the size, while Axsome Therapeutics is growing revenue faster (+65.5% vs +12.9%).
On valuation, BioMarin Pharmaceutical trades at a lower forward P/E (8.3x vs 35.8x for Axsome Therapeutics). BioMarin Pharmaceutical converts more of its revenue into profit, with a net margin of 10.8% versus -28.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | BMRN |
|---|---|---|
| Share price | $168.35 | $54.80 |
| Market cap | $8.82B | $10.61B |
| 1-day change | -1.02% | -0.17% |
| YTD return | -7.82% | -7.64% |
| 1-year return | +37.41% | +0.37% |
| 5-year return | +319.83% | -27.67% |
| P/E ratio (TTM) | — | 148.09 |
| Forward P/E | 35.80 | 8.26 |
| EPS (TTM) | $-3.70 | $0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $3.22B |
| Revenue growth (YoY) | +65.55% | +12.87% |
| Net income (latest FY) | $-183.17M | $348.90M |
| Gross margin | 92.56% | 77.73% |
| Operating margin | -26.12% | 12.71% |
| Net margin | -28.69% | 10.83% |
| 52-week high | $260.19 | $70.98 |
| 52-week low | $119.20 | $49.26 |
| Distance from 52-week high | -35.30% | -22.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +69.07% | +67.21% |
| Average volume | 710.84K | 2.04M |
| Shares outstanding | 52.38M | 193.57M |
| Employees | 1,346 | 3,221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AXSM has outperformed BMRN by 37.0 percentage points over the past year.
- BioMarin Pharmaceutical is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
- Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs +12.87%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
AXSM vs BMRN FAQ
Which is bigger, Axsome Therapeutics or BioMarin Pharmaceutical?
BioMarin Pharmaceutical (BMRN) is larger, with a market capitalization of $10.61B compared with $8.82B for Axsome Therapeutics (AXSM).
Which stock has performed better over the past year, AXSM or BMRN?
AXSM returned +37.41% over the past 12 months, compared with +0.37% for BMRN (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and BioMarin Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.